Revisiting beta 2 glycoprotein I, the major autoantigen in the antiphospholipid syndrome

Iranian Journal of Immunology

Volumn 9, Issue 2, 2012, Pages 73-85

  Rahgozar, Soheila ^a  

^a UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

Autoantibodies; Coagulation; Fibrinolysis; 2 glycoprotein I

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CELL LEVEL; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; MOLECULAR WEIGHT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; FIBRINOLYSIS; HUMANS;

EID: 84871892921     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Schultze HE. [Glycoproteins of human plasma]. Bull Schweiz Akad Med Wiss. 1961; 17:77-91.
2. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 1984; 81:3640-4.
3. Wurm H. beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem. 1984; 16:511-5.
4. Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta. 1986; 884:142-9.
5. Nimpf J, Wurm H, Kostner GM. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis. 1987; 63:109-14.
6. Polz, E, Isolation of a specific lipid binding protein from human serum by affinity chromatography using heparin-sepharose. In: Peeters, H. Protides of Biological Fluids. Oxford: Pergamon Press; 1979, p. 817-820.
7. Kroll J, Larsen JK, Loft H, Ezban M, Wallevik K, Faber M. DNA-binding proteins in Yoshida ascites tumor fluid. Biochim Biophys Acta. 1976; 434:490-501.
8. Polz E, Kostner GM, Holasek A. Studies on the protein composition of human serum very low density lipoproteins: demonstration of the beta 2-glycoprotein-I. Hoppe Seylers Z Physiol Chem. 1979; 360:1061-7.
9. Polz E, Kostner GM. The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett. 1979; 102:183-6.
10. Polz E, Kostner GM. Binding of beta 2-glycoprotein-I to intralipid: determination of the dissociation constant. Biochem Biophys Res Commun. 1979; 90:1305-12.
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87:4120-4.
12. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336:177-8.
13. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990; 335:1544-7.
14. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007; 109:422-30.
15. Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr Rheumatol Rep. 2010; 13:90-5.
16. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost. 1992; 67:649-53.
17. Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, et al. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis. 2000; 152:337-46.
18. Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem. 2001; 276:13817-21.
19. Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, et al. Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem. 2000; 128:1017-24.
20. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999; 81:87-95.
21. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, et al. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood. 2010; 116:1961-70.
22. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003; 101:157-62.
23. Arad A, Proulle V, Furie RA, Furie BC, Furie B. beta-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011; 117:3453-9.
24. Reddel S, Krilis S. The anti-phospholipid syndrome. In: Theofilopoulos A, Bona C. The molecular pathology of autoimmune diseases. 2nd ed. New York: Taylor and Francis; 2002. p. 325-52.
25. Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry. 1996; 35:13833-42.
26. Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J. 1991; 277:387-91.
27. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J. 1999; 18:6228-39.
28. Hunt J, Krilis S. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994; 152:653-9.
29. Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood. 1998; 91:4173-9.
30. Shi T, Giannakopoulos B, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318. J Biol Chem. 2005; 280:907-12.
31. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A. 1993; 90:2141-5.
32. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999; 18:5166-74.
33. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood. 2010; 116:1995-7.
34. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, et al. Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost. 2010; 8:1754-62.
35. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost. 2011; 9 Suppl.1:275-82.
36. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116:1336-43.
37. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295-306.
38. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost. 2007; 5:2421-8.
39. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009; 8:998-1005.
40. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003; 23:17-25.
41. Carson SD, Ross SE. Effects of lipid-binding proteins apo A-I, apo A-IL, beta 2-glycoprotein I, and C-reactive protein on activation of factor X by tissue factor--factor VIIa. Thromb Res. 1988; 50:669-78.
42. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001; 44:2870-8.
43. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol. 2004; 16:1633-41.
44. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, Derksen RH, Pennings MT, Papalardo E, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011; 117:1408-14.
45. Schousboe I. Inositolphospholipid-accelerated activation of prekallikrein by activated factor XII and its inhibition by beta 2-glycoprotein I. Eur J Biochem. 1988; 176:629-36.
46. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Thromb Haemost. 1995; 73:798-804.
47. McNally T, Mackie IJ, Isenberg DA, Machin SJ. beta 2 glycoprotein-I inhibits factor XII activation on triglyceride rich lipoproteins: the effect of antibodies from plasma of patients with antiphospholipid syndrome. Thromb Haemost. 1996; 76:220-5.
48. Shi T, Iverson GM, Qi JC, Cockerill KA, Linnik MD, Konecny P, et al. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 2004; 101:3939-44.
49. Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum. 2007; 56:605-13.
50. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost. 2007; 5 Suppl.1:102-15.
51. Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN. Inhibition of prothrombin activation by antiphospholipid antibodies and beta 2-glycoprotein 1. Br J Haematol. 1994; 87: 548-54.
52. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost. 1993; 70:342-5.
53. Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol. 1993; 83:466-72.
54. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007; 100:1673-85.
55. Nimpf J, Wurm H, Kostner GM. Interaction of beta 2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost. 1985; 54:397-401.
56. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood. 2007; 110:1483-91.
57. Keeling DM, Wilson AJ, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol. 1993; 46:908-11.
58. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol. 1998; 112:325-33.
59. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995; 95:309-16.
60. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost. 1988; 60:54-8.
61. Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin thrombomodulin complex. Biochem J. 1986; 238:151-7.
62. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996; 75:49-55.
63. Matsuda J, Gotoh M, Gohchi K, Kawasugi K, Tsukamoto M, Saitoh N. Resistance to activated protein C activity of an antibeta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I. Br J Haematol. 1995; 90:204-6.
64. Izumi T, Pound ML, Su Z, Iverson GM, Ortel TL. Anti-beta (2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta (2)-glycoprotein I to phospholipids. Thromb Haemost. 2002; 88:620-6.
65. Walker FJ. Does beta-2-glycoprotein I inhibit interaction between protein S and C4b-binding protein? Thromb Haemost. 1993; 69 [Abstract]:930.
66. Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost. 1999; 81:748-57.
67. Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost. 2003; 1:1764-70.
68. Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost. 2000; 84:653-6.
69. Lean SY, Ellery P, Ivey L, Thom J, Oostryck R, Leahy M, et al. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation. Haematologica. 2006; 91:1360-6.
70. Cucnik S, Krizaj I, Rozman B, Kveder T, Bozic B. Concomitant isolation of protein C inhibitor and unnicked beta2-glycoprotein I. Clin Chem Lab Med. 2004; 42:171-4.
71. Schousboe I. Binding of beta 2-glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res. 1980; 19:225-37.
72. Nimpf J, Gries A, Wurm H, Kostner GM. Influence of beta 2-glycoprotein-I upon the content of cAMP and cGMP in human blood platelets. Thromb Haemost. 1985; 54:824-7.
73. Rahgozar S, Giannakopoulos B, Yan X, Wei J, Cheng Qi J, Gemmell R, et al. Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies. Arthritis Rheum. 2008; 58:1146-55.
74. Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost. 1992; 68:516-20.
75. Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. Thromb Haemost. 1996; 76:190-4.
76. Francis RB Jr, McGehee WG, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost. 1988; 59:412-4.
77. Violi F, Ferro D, Valesini G, Quintarelli C, Saliola M, Grandilli MA, et al. Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. BMj. 1990; 300:1099-102.
78. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005; 129:307-21.
79. Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood. 2004; 103:3766-72.
80. Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 1993; 318:317-21.
81. Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976; 73:4179-83.
82. Gladysheva IP, Sazonova IY, Houng A, Hedstrom L, Reed GL. Regulation of nonproteolytic active site formation in plasminogen. Biochemistry. 2007; 46:8879-87.
83. Marder VJ, Rothbard RL, Fitzpatrick PG, Francis CW, Norry EC. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction. Drugs. 1987; 33 Suppl 3:124-32.
84. Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol. 2002; 119:781-8.
85. Lopez-Lira F, Rosales-Leon L, Martinez VM, Ruiz Ordaz BH. The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. Biochim Biophys Acta. 2006; 1764:815-23.
86. Ieko M, Ichikawa K, Atsumi T, Takeuchi R, Sawada KI, Yasukouchi T, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost. 2000; 26:85-90.
87. Arvieux J, Regnault V, Hachulla E, Darnige L, Berthou F, Youinou P. Oxidation of beta2-glycoprotein I (beta2GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodies. Thromb Haemost. 2001; 86:1070-6.
88. Buttari B, Profumo E, Mattei V, Siracusano A, Ortona E, Margutti P, et al. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type I response. Blood. 2005; 106:3880-7.